Trial Review

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00800436




Registration number
NCT00800436
Ethics application status
Date submitted
1/12/2008
Date registered
2/12/2008
Date last updated
16/12/2016

Titles & IDs
Public title
A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females
Scientific title
An Open-Label, Two-Part, Multi-Centre, Trastuzumab Dose-Finding Study in Healthy Male Volunteers and HER2 Positive Female Patients
Secondary ID [1] 0 0
BP22023
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Herceptin

Experimental: Part 1: Cohort 1 - Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.

Experimental: Part 1: Cohort 2 - Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.

Experimental: Part 1: Cohort 3 - Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.

Experimental: Part 1: Cohort 4 - Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.

Experimental: Part 1: Cohort 5 - Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.

Experimental: Part 2: Cohort A - Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.

Experimental: Part 2: Cohort B - Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.


Treatment: Drugs: Herceptin
Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Trastuzumab
Timepoint [1] 0 0
Predose (0 hours) and postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Secondary outcome [1] 0 0
Trough Serum Concentration on Day 22 (CDay22) of Trastuzumab
Timepoint [1] 0 0
Day 22
Secondary outcome [2] 0 0
Maximum Observed Serum Concentration of Trastuzumab (Cmax)
Timepoint [2] 0 0
Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Secondary outcome [3] 0 0
Time to Maximum Serum Concentration (Tmax) of Trastuzumab
Timepoint [3] 0 0
Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Secondary outcome [4] 0 0
Terminal Elimination Half-Life (T1/2) of Trastuzumab
Timepoint [4] 0 0
Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)

Eligibility
Key inclusion criteria
* Healthy Participants (Part 1 only)

* Males 18 to 45 to years of age
* Baseline left ventricular ejection fraction (LVEF) greater than (>) 60 percent (%)
* HER2-Positive Females (Parts 1 and 2)

* Females greater than or equal to (=) 18 years of age
* Eastern Cooperative Oncology Group (ECOG) performance status of 0
* Previous non-metastatic operable primary invasive HER2-positive breast cancer
* Baseline LVEF >55%
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Healthy Participants (Part 1 only)

* Clinically significant abnormalities in laboratory test results or electrocardiogram
* History of significant allergies, gastrointestinal, renal, hepatic, cardiovascular, or pulmonary disease
* History of hypersensitivity or allergic reaction, spontaneous or following drug administration
* History of cardiac conditions
* HER2-Positive Females (Parts 1 and 2)

* Metastatic disease
* Concurrent other malignancy requiring therapy of any modality which may interfere with PK investigations or result in unexpected toxicity
* Use of Herceptin in previous 5 months
* Serious cardiac illness

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2009
Sample size
Target
Accrual to date
Final
66
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- East Bentleigh
Recruitment postcode(s) [1] 0 0
VIC 3165 - East Bentleigh
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Christchurch
Country [2] 0 0
New Zealand
State/province [2] 0 0
Grafton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00800436